- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00817648
A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia
A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a rater- blind, parallel assignment, randomized and active controlled study. The subjects investigated are outpatients or inpatient with schizophrenia from the Chinese Han race. The screening phase lasts for 1 week. The eligible patients enter the next randomized treatment phase. The titration duration is 1 week. After the first week, the patients are administered with a flexible dose regimen. In this study, the effective doses range of seroquel and risperidone are 600-750mg/d and 3-6mg/d respectively and the treatment duration lasts for 6 weeks.
The efficacy and safety of seroquel in the treatment of patients with schizophrenia have been confirmed by multiple double blind studies. This study is designed to evaluate the efficacy and safety of seroquel in the treatment of Chinese Han patients with schizophrenia. Therefore, the single blind and active control design should be selected for this study. The drug titration method and dose are within the range specified in the instruction and patients with schizophrenia are tolerant to the drug in clinical treatment.
The purpose of schizophrenic patient treatment is to improve the core symptoms, prevent suicide and other aggressive behavior, alleviate the side reactions caused by the drug, and recover the life functions of patients. Generally, the treatment in the acute phase lasts for 6 to 8 weeks. In this study, the treatment in the acute phase lasts for 6 weeks.
The rating scales used in this study are standard psychiatric rating scales with good validity and are widely used in the study of antischizophrenia drugs and in the treatment of patients with schizophrenia in China. The PANSS is developed from two early rating scales, namely the brief psychiatric rating scale (BPRS) and the psychiatric rating scale. The high inter-investigator reliability and repeated measurement reliability of these scales have been proved by multiple studies. The clinical global impression (CGI) is a simple but convenient global impression scale. It is applicable to any patients treated and studied by the psychiatric department. The Carlgary depression scale for schizophrenia (CDSS) is used to evaluate the depressive symptoms of patients with schizophrenia. It has good reliability and validity. The abnormal involuntary movement scale (AIMS) is another evaluation tool consisting of 12 items. The AIMS is used to evaluate the abnormal involuntary movements related to antischizophrenia drugs. The AIMS is nearly the most frequently used multi-item rating scale evaluating of tardive dyskinesia. The Simpson and Angus scale (SAS) is also a rating scale commonly used since its release in 1970. The validity of SAS has been verified in the double blind and placebo-controlled study involving two haloperidol doses.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Shanghai Mental Health Center
-
Shanghai, Shanghai, China, 200020
- Mental Health Center of Luwan District
-
Shanghai, Shanghai, China, 201108
- Branch Hospital of Shanghai Mental Health Center
-
-
Zhejiang
-
Huzhou, Zhejiang, China, 313000
- Huzhou Third People Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent provided by legal guardians or patients.
- Patients who met DSM-IV criteria for schizophrenia: 295.20 (Schizophrenia, Catatonic Type), 295.10 (Schizophrenia, Disorganized Type), 295.30 (Schizophrenia, Paranoid Type), 295.60 (Schizophrenia, Residual Type), and 296.90 (Mood Disorder NOS).
- Age from 18-65 years old, male or female, Han nationality.
- PANSS total score at least 70 at baseline.
- Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrolment.
- Able to understand and comply with the requirements of the study. -
Exclusion Criteria:
- Pregnancy or lactation.
- A diagnosis of any DSM-IV Axis I disorders that is not defined in the inclusion criteria, except schizophrenia.
- Patients who have an imminent risk of suicide or a danger to self or others as judged by investigator.
- Known intolerance or lack of efficacy to seroquel and/or risperidone, as judged by the investigator.
- Use of seroquel and/or risperidone within 28 days prior to enrolment.
- Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir.
- Use of any of the following cytochrome P450 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids.
- Use of a long acting antipsychotics Within one dosing interval
- Substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria.
- Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse as defined by DSM-IV criteria within 28 days prior to enrolment.
- Medical conditions that would affect the absorption, distribution, metabolism, or excretion of study treatment.
- Unstable or inadequately treated medical illness (e.g. CHF - congestive heart failure, angina pectoris, hypertension) as judged by the investigator.
- Involvement in the planning and conduct of the study.
- Participation in another drug trial within 28 days prior enrolment into this study.
- Patient with diabetes mellitus.
- The patient's absolute neutrophil count (ANC) ≤ 1.5 x 109/L and the ALT and AST values in the liver function test exceeding two times of the upper limits of normal values.
- Use of Electroconvulsive therapy within 28 days prior to randomization.
- Use of clozapine within 28 days prior to randomization.
- Previous enrolment in the present study -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Quetiapine fumarate, flexible doses(600-750 mg/d)
|
Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6.
If a patient is intolerant, the doses can be adjusted as judged by investigator.
Other Names:
|
ACTIVE_COMPARATOR: 2
risperidone, flexible doses(3-6 mg/d)
|
risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6.
If a patient is intolerant, the doses can be adjusted as judged by investigator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the change of PANSS total score
Time Frame: from the baseline to week 6
|
from the baseline to week 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The Carlgary depression scale for schizophrenia (CDSS)
Time Frame: from the baseline to week 6
|
from the baseline to week 6
|
The abnormal involuntary movement scale (AIMS)
Time Frame: from the baseline to Week 6
|
from the baseline to Week 6
|
The Simpson and Angus scale (SAS)
Time Frame: from the baseline to week 6
|
from the baseline to week 6
|
The clinical global impression (CGI),including CGI-I and CGI-S
Time Frame: from the baseline to week 6
|
from the baseline to week 6
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Mandrioli R, Fanali S, Ferranti A, Raggi MA. HPLC analysis of the novel antipsychotic drug quetiapine in human plasma. J Pharm Biomed Anal. 2002 Nov 7;30(4):969-77. doi: 10.1016/s0731-7085(02)00395-3.
- Davis PC, Wong J, Gefvert O. Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J Pharm Biomed Anal. 1999 Jun;20(1-2):271-82. doi: 10.1016/s0731-7085(99)00036-9.
- Riedel M, Muller N, Strassnig M, Spellmann I, Engel RR, Musil R, Dehning S, Douhet A, Schwarz MJ, Moller HJ. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):432-7. doi: 10.1007/s00406-005-0622-6. Epub 2005 Nov 4.
- Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin. 2004 Sep;20(9):1357-63. doi: 10.1185/030079904125004510.
- Miodownik C, Lerner V. Quetiapine: efficacy, tolerability and safety in schizophrenia. Expert Rev Neurother. 2006 Jul;6(7):983-92. doi: 10.1586/14737175.6.7.983.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Quetiapine Fumarate
- Risperidone
Other Study ID Numbers
- D1443L00071
- SMHC-098
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Quetiapine
-
Mayo ClinicCompletedDelirium | DementiaUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedBipolar Disorder | Cannabis-Related DisorderUnited States
-
Centro de Investigación Biomédica en Red de Salud...Completed
-
Federal Stare Budgetary Scientific Institution,...Kazan State Medical University; Federal State Budgetary Institution V.M. Bekhterev...RecruitingBipolar Affective DisorderRussian Federation
-
University of CincinnatiNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedBipolar Disorder | Alcohol AbuseUnited States
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...Recruiting
-
University of CincinnatiCompleted
-
University of Texas Southwestern Medical CenterCompletedBipolar Disorder | Cocaine DependenceUnited States
-
Otsuka Pharmaceutical Development & Commercialization...PRA Health SciencesCompletedSchizophrenia | Bipolar DisorderUnited States
-
The University of Texas Health Science Center at...AstraZenecaCompletedBipolar DisorderUnited States